Mizuho analyst Difei Yang upgraded Audentes Therapeutics to Buy and raised her price target for the shares to $45 from $38. The analyst is “increasingly positive” on the company’s AT-132 program. X-Linked myotubular myopathy patients treated so far with AT-132 continue to show significant improvements in neuromuscular and respiratory function, Yang tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.